45 CFR § 180 compliance
A · 100
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
11,000
Insurances with rates
14
CPT / HCPCS codes
7,408
Source MRF
Most expensive procedures (gross)
J0225
$292,410
VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE
Gross
$596,755
J0225
$292,410
VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE
Gross
$596,755
A9513
$116,375
LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION
Gross
$237,500
A9513
$116,375
LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION
Gross
$237,500
J1823
$106,983
INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION
Gross
$218,333
J1823
$106,983
INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION
Gross
$218,333
J2351
$101,141
OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN
Gross
$206,410
J2351
$101,141
OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN
Gross
$206,410
C9293
$100,876
GLUCARPIDASE 1000 UNIT INTRAVENOUS SOLUTION
Gross
$205,870
C9293
$100,876
GLUCARPIDASE 1000 UNIT INTRAVENOUS SOLUTION
Gross
$205,870
J9228
$86,996
IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION
Gross
$177,544
J9228
$86,996
IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION
Gross
$177,544
J1747
$62,638
SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION
Gross
$127,833
J1747
$62,638
SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION
Gross
$127,833
J2327
$52,920
RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE
Gross
$108,000
J2327
$52,920
RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE
Gross
$108,000
J2350
$48,300
OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION
Gross
$98,572
J2350
$48,300
OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION
Gross
$98,572
J9309
$44,270
POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION
Gross
$90,347
J9309
$44,270
POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION
Gross
$90,347
J0638
$41,953
CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION
Gross
$85,619
J0638
$41,953
CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION
Gross
$85,619
J9334
$38,644
EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11200 UNIT/5.6 ML SUBCUT SOLN
Gross
$78,865
J9334
$38,644
EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11200 UNIT/5.6 ML SUBCUT SOLN
Gross
$78,865
J3241
$37,905
TEPROTUMUMAB-TRBW 500 MG INTRAVENOUS SOLUTION
Gross
$77,358
J3241
$37,905
TEPROTUMUMAB-TRBW 500 MG INTRAVENOUS SOLUTION
Gross
$77,358
J2507
$37,696
PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION
Gross
$76,930
J2507
$37,696
PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION
Gross
$76,930
J9298
$35,605
NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION
Gross
$72,662
J9298
$35,605
NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION
Gross
$72,662
J1628
$34,439
GUSELKUMAB 200 MG/2 ML SUBCUTANEOUS SYRINGE
Gross
$70,283
J1628
$34,439
GUSELKUMAB 200 MG/2 ML SUBCUTANEOUS SYRINGE
Gross
$70,283
J3245
$32,629
TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE
Gross
$66,589
J3245
$32,629
TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE
Gross
$66,589
J3357
$29,634
USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SOLUTION
Gross
$60,477
J3357
$29,634
USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SOLUTION
Gross
$60,477
J9042
$28,768
BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION
Gross
$58,710
J9042
$28,768
BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION
Gross
$58,710
J9272
$27,774
DOSTARLIMAB-GXLY 50 MG/ML INTRAVENOUS SOLUTION
Gross
$56,682
J9272
$27,774
DOSTARLIMAB-GXLY 50 MG/ML INTRAVENOUS SOLUTION
Gross
$56,682
J9043
$27,664
CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION
Gross
$56,456
J9043
$27,664
CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION
Gross
$56,456
J9022
$27,567
ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION
Gross
$56,259
J9022
$27,567
ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION
Gross
$56,259
J1640
$26,804
HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION
Gross
$54,702
J1640
$26,804
HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION
Gross
$54,702
J9144
$25,772
DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN
Gross
$52,595
J9144
$25,772
DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN
Gross
$52,595
J2329
$25,658
UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION
Gross
$52,363
J2329
$25,658
UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION
Gross
$52,363
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J0225 | VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE | $596,755 | $292,410 | $340,150 | $584,820 | 21 |
| J0225 | VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE | $596,755 | $292,410 | $208,864 | $584,820 | 31 |
| A9513 | LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION | $237,500 | $116,375 | $135,375 | $232,750 | 21 |
| A9513 | LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION | $237,500 | $116,375 | $279 | $232,750 | 33 |
| J1823 | INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION | $218,333 | $106,983 | $124,450 | $213,966 | 21 |
| J1823 | INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION | $218,333 | $106,983 | $474 | $213,966 | 33 |
| J2351 | OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN | $206,410 | $101,141 | $117,653 | $202,281 | 21 |
| J2351 | OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN | $206,410 | $101,141 | $72,243 | $202,281 | 31 |
| C9293 | GLUCARPIDASE 1000 UNIT INTRAVENOUS SOLUTION | $205,870 | $100,876 | $117,346 | $201,753 | 21 |
| C9293 | GLUCARPIDASE 1000 UNIT INTRAVENOUS SOLUTION | $205,870 | $100,876 | $385 | $201,753 | 33 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $177,544 | $86,996 | $101,200 | $173,993 | 21 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $177,544 | $86,996 | $189 | $173,993 | 33 |
| J1747 | SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION | $127,833 | $62,638 | $72,865 | $125,276 | 21 |
| J1747 | SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION | $127,833 | $62,638 | $44,741 | $125,276 | 31 |
| J2327 | RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE | $108,000 | $52,920 | $61,560 | $105,840 | 21 |
| J2327 | RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE | $108,000 | $52,920 | $37,800 | $105,840 | 31 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $98,572 | $48,300 | $56,186 | $96,600 | 21 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $98,572 | $48,300 | $58.76 | $96,600 | 33 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $90,347 | $44,270 | $51,498 | $88,540 | 21 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $90,347 | $44,270 | $136 | $88,540 | 33 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $85,619 | $41,953 | $48,803 | $83,906 | 21 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $85,619 | $41,953 | $124 | $83,906 | 33 |
| J9334 | EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11200 UNIT/5.6 ML SUBCUT SOLN | $78,865 | $38,644 | $44,953 | $77,288 | 21 |
| J9334 | EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11200 UNIT/5.6 ML SUBCUT SOLN | $78,865 | $38,644 | $27,603 | $77,288 | 31 |
| J3241 | TEPROTUMUMAB-TRBW 500 MG INTRAVENOUS SOLUTION | $77,358 | $37,905 | $44,094 | $75,811 | 21 |
| J3241 | TEPROTUMUMAB-TRBW 500 MG INTRAVENOUS SOLUTION | $77,358 | $37,905 | $333 | $75,811 | 33 |
| J2507 | PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION | $76,930 | $37,696 | $43,850 | $75,391 | 21 |
| J2507 | PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION | $76,930 | $37,696 | $3,392 | $75,391 | 33 |
| J9298 | NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION | $72,662 | $35,605 | $41,418 | $71,209 | 21 |
| J9298 | NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION | $72,662 | $35,605 | $25,432 | $71,209 | 31 |
| J1628 | GUSELKUMAB 200 MG/2 ML SUBCUTANEOUS SYRINGE | $70,283 | $34,439 | $40,061 | $68,877 | 21 |
| J1628 | GUSELKUMAB 200 MG/2 ML SUBCUTANEOUS SYRINGE | $70,283 | $34,439 | $139 | $68,877 | 33 |
| J3245 | TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE | $66,589 | $32,629 | $37,956 | $65,257 | 21 |
| J3245 | TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE | $66,589 | $32,629 | $140 | $65,257 | 33 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SOLUTION | $60,477 | $29,634 | $34,472 | $59,268 | 21 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SOLUTION | $60,477 | $29,634 | $153 | $59,268 | 33 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $58,710 | $28,768 | $33,465 | $57,536 | 21 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $58,710 | $28,768 | $253 | $57,536 | 33 |
| J9272 | DOSTARLIMAB-GXLY 50 MG/ML INTRAVENOUS SOLUTION | $56,682 | $27,774 | $32,309 | $55,548 | 21 |
| J9272 | DOSTARLIMAB-GXLY 50 MG/ML INTRAVENOUS SOLUTION | $56,682 | $27,774 | $19,839 | $55,548 | 31 |
| J9043 | CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION | $56,456 | $27,664 | $32,180 | $55,327 | 21 |
| J9043 | CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION | $56,456 | $27,664 | $232 | $55,327 | 33 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $56,259 | $27,567 | $32,068 | $55,134 | 21 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $56,259 | $27,567 | $91.86 | $55,134 | 33 |
| J1640 | HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION | $54,702 | $26,804 | $31,180 | $53,608 | 21 |
| J1640 | HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION | $54,702 | $26,804 | $31.35 | $53,608 | 33 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $52,595 | $25,772 | $29,979 | $51,543 | 21 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $52,595 | $25,772 | $53.4 | $51,543 | 33 |
| J2329 | UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION | $52,363 | $25,658 | $29,847 | $51,315 | 21 |
| J2329 | UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION | $52,363 | $25,658 | $18,327 | $51,315 | 31 |
Showing top 50 of 11,000 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.